Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Rectal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
1 drug · 2 active trials
1 drug · 47 active trials
Data updated 6 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nivolumab | Phase 2 | Phase 2 | 12 | 1 | 0 | 18 | 0 | — | — | Aug 17, 2015 |
| Sintilimab | Phase 2 | Phase 2 | 7 | 5 | 0 | 9 | 0 | — | — | Aug 14, 2020 |
| Pembrolizumab | Phase 2 | Phase 2 | 4 | 2 | 0 | 8 | 0 | — | — | Jun 14, 2016 |
| Zanidatamab | Phase 2 | Phase 2 | 3 | 2 | 0 | 3 | 0 | — | — | Feb 15, 2023 |
| Ipilimumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 7 | 0 | — | — | 2013-02 |
| Cyclophosphamide | Phase 2 | Phase 2 | 2 | 2 | 0 | 6 | 0 | — | — | 2012-02 |
| Aldesleukin | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | 2000-07 |
| Camrelizumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | Nov 10, 2019 |
| Trastuzumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | Aug 17, 2015 |
| Fludarabine | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Sep 21, 2017 |
| Encorafenib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Jun 14, 2019 |
| Raltitrexed | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | 2006-12 |
| Tucatinib | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Dec 30, 2022 |
| Cabozantinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Jun 23, 2021 |
| Regorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 11 | 0 | — | — | 2014-10 |
| FOLFIRI Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | 2004-12 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2007-07 |
| Fruquintinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Dec 11, 2017 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2007-10 |
| Temozolomide | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | May 10, 2013 |
| Toripalimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Sep 1, 2022 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Nov 26, 2012 |
| Binimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Immunomodulatory Oligonucleotide | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jan 25, 2022 |
| Palbociclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2009-10 |
| Abemaciclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 2, 2020 |
| Adavosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Adebrelimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 1, 2024 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dostarlimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jan 31, 2026 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Mitomycin | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 9, 2022 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Sunitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 29, 2024 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Panitumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 12 | 0 | — | — | 2004-12 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2006-10 |
| Durvalumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | May 14, 2018 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2001-12 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.